NC COVID-19 Vaccine Plan Update Oct 9, 2020 Task Force Meeting Overview

The NC COVID-19 Vaccine Plan discussed in the October 9, 2020 Task Force Meeting includes details on vaccine supply, distribution goals, clinical trial timelines, safety, and outreach strategies. Key points cover vaccine development progress, trial protocols, distribution targets, and communication plans for prioritization and education. The plan aims to achieve 100 million doses by December, with further targets for 2021. Clinical trials involve mRNA and viral vector vaccines with specific efficacy goals. Resources for vaccination programs and CDC strategies are provided for jurisdictions.

• COVID-19
• Vaccine Plan
• Task Force Meeting
• Clinical Trials
• Outreach

azent Follow

Uploaded on Nov 15, 2024 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

Presentation Transcript

1. NC COVID-19 Vaccine Plan - Update October 9, 2020 Task Force Meeting

2. Overview Vaccines in queue Supply & Demand Allocation Outreach & Education

3. Clinical Trial Timeline Start dt: July 27 Earliest Proj Eval: Late-Oct Earliest Reg Approval: Dec Start dt: July 27 Earliest Proj Eval: Mid-Nov Start dt: Aug 18 Earliest Proj Eval: Mid-Nov Start dt: Sept 23 Earliest Proj Eval: Dec Phase 2/3 study protocol Placebo-controlled, randomized, observer- blind study in healthy individuals N=30,000 Efficacy target of 60% Phase 3 study protocol Placebo-controlled, randomized, stratified, observer-blind study in adults N=30,000 Efficacy target of 60% As of 9/21, 25,976 participants have received the second injection Phase 2/3 study protocol Placebo-controlled, randomized, double- blind study in adults N=30,000 Efficacy target of 50% *Global trials halted Sept 6, resumed in Brazil and England Sept 12 Phase 3 protocol Placebo-controlled, randomized, double-blind study in adults N=60,000 Efficacy target 60% Study Info mRNA vaccine Two dose regimen Ultra-cold temperature requirements mRNA vaccine Two dose regimen Viral vector vaccine Viral vector vaccine Single dose No ultra-cold temperature req. Vaccine Details Distribution Goals 100 million doses by December 500 million doses/year starting 2021 400 million doses in 2020 1 billion doses in 2021 Will not seek EUA until Nov 25th at earliest Phase 1 results suggest immune response triggered in older adults w/o adverse events 31% of participants from diverse communities

5. Outreach and Education Communication Plan Rationale for Prioritization Safety of Vaccine

6. Resources Vaccination Program Action Items for Jurisdictions COVID-19 Interim Playbook CDC Strategy for distribution Operation Warp Speed Vaccine Distribution Process -Infographic Vaccination Planning Assumptions LHD FAQ All resources linked to the NCCHCA website